Tags

Type your tag names separated by a space and hit enter

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
Blood 2011; 118(17):4585-90Blood

Abstract

The appropriate therapy for limited-stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is unclear. In contrast to classical Hodgkin lymphoma (CHL), chemotherapy is often omitted; however, it is unknown whether this impacts the risk of relapse. Herein, we compared the outcome of patients with limited-stage NLPHL treated in an era in which ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy was routinely incorporated into the primary therapy to an earlier era in which radiotherapy (RT) was used as a single modality. Using the British Columbia Cancer Agency Lymphoid Cancer Database, 88 patients with limited-stage NLPHL (stage 1A/1B or 2A, nonbulky disease < 10 cm) were identified. Treatment followed era-specific guidelines: before 1993, (n = 32) RT alone; and 1993 to present (n = 56), ABVD-like chemotherapy for 2 cycles followed by RT with the exception of 14 patients who received ABVD chemotherapy alone. Most patients were male (75%) with stage I disease (61%). In an era-to-era comparison, the 10-year time to progression (98% vs 76% P = .0074), progression-free survival (91% vs 65% P = .0024), and OS (93% vs 84%, P = .074) favored the ABVD treatment era compared with the RT alone era. Treating limited-stage NLPHL similarly to CHL may improve outcome compared with the use of radiation alone.

Authors+Show Affiliations

Department of Medical Oncology, University of British Columbia, Vancouver, BC, Canada. ksavage@bccancer.bc.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Studies
Journal Article

Language

eng

PubMed ID

21873543

Citation

Savage, Kerry J., et al. "Treating Limited-stage Nodular Lymphocyte Predominant Hodgkin Lymphoma Similarly to Classical Hodgkin Lymphoma With ABVD May Improve Outcome." Blood, vol. 118, no. 17, 2011, pp. 4585-90.
Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011;118(17):4585-90.
Savage, K. J., Skinnider, B., Al-Mansour, M., Sehn, L. H., Gascoyne, R. D., & Connors, J. M. (2011). Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood, 118(17), pp. 4585-90. doi:10.1182/blood-2011-07-365932.
Savage KJ, et al. Treating Limited-stage Nodular Lymphocyte Predominant Hodgkin Lymphoma Similarly to Classical Hodgkin Lymphoma With ABVD May Improve Outcome. Blood. 2011 Oct 27;118(17):4585-90. PubMed PMID: 21873543.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. AU - Savage,Kerry J, AU - Skinnider,Brian, AU - Al-Mansour,Mubarak, AU - Sehn,Laurie H, AU - Gascoyne,Randy D, AU - Connors,Joseph M, Y1 - 2011/08/26/ PY - 2011/8/30/entrez PY - 2011/8/30/pubmed PY - 2012/1/4/medline SP - 4585 EP - 90 JF - Blood JO - Blood VL - 118 IS - 17 N2 - The appropriate therapy for limited-stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is unclear. In contrast to classical Hodgkin lymphoma (CHL), chemotherapy is often omitted; however, it is unknown whether this impacts the risk of relapse. Herein, we compared the outcome of patients with limited-stage NLPHL treated in an era in which ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy was routinely incorporated into the primary therapy to an earlier era in which radiotherapy (RT) was used as a single modality. Using the British Columbia Cancer Agency Lymphoid Cancer Database, 88 patients with limited-stage NLPHL (stage 1A/1B or 2A, nonbulky disease < 10 cm) were identified. Treatment followed era-specific guidelines: before 1993, (n = 32) RT alone; and 1993 to present (n = 56), ABVD-like chemotherapy for 2 cycles followed by RT with the exception of 14 patients who received ABVD chemotherapy alone. Most patients were male (75%) with stage I disease (61%). In an era-to-era comparison, the 10-year time to progression (98% vs 76% P = .0074), progression-free survival (91% vs 65% P = .0024), and OS (93% vs 84%, P = .074) favored the ABVD treatment era compared with the RT alone era. Treating limited-stage NLPHL similarly to CHL may improve outcome compared with the use of radiation alone. SN - 1528-0020 UR - https://www.unboundmedicine.com/medline/citation/21873543/Treating_limited_stage_nodular_lymphocyte_predominant_Hodgkin_lymphoma_similarly_to_classical_Hodgkin_lymphoma_with_ABVD_may_improve_outcome_ L2 - http://www.bloodjournal.org/cgi/pmidlookup?view=long&amp;pmid=21873543 DB - PRIME DP - Unbound Medicine ER -